Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Subscribe To Our Newsletter & Stay Updated
